Flexitouch Lymphedema System in Treating Stage II Lymphedema in Patients With Breast Cancer

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

RATIONALE: The Flexitouch lymphedema system may lessen lymphedema caused by treatment for breast cancer. It is not yet known whether the Flexitouch lymphedema system is more effective than complex decongestive therapy in treating lymphedema. PURPOSE: This randomized clinical trial is studying the Flexitouch lymphedema system in treating stage II lymphedema in patients with breast cancer.

Condition or disease	Intervention/treatment	Phase
Breast Cancer; Lymphedema	Other: questionnaire administration; Other: lymphedema management	Not Applicable

Detailed Description:

PRIMARY OBJECTIVES: I. To quantitatively assess, by circumferential measurements and CT imaging techniques, the ability of the Flexitouch Lymphedema System to maintain reductions in limb volume after completion of the reductive phase of complex decongestive therapy in a population of patients with upper limb lymphedema secondary to the effects of breast cancer treatment. SECONDARY OBJECTIVES: I. To determine the drainage territory of the lymphatics of the affected arm and chest using CT and to determine whether these patterns are changed by treatment with the Flexitouch Lymphedema System/daytime garments versus Flexitouch Lymphedema System/daytime garments/nighttime bandaging versus standard self-care. OUTLINE: Patients are randomized to 1 of 3 treatment arms. Arm I: Patients undergo complex decongestive therapy comprising daily compression garment (sleeve and glove) use, daily manual lymphatic drainage (self-administered), and nighttime bandaging with low stretch Comprilan bandages. Arm II: Patients undergo daily compression with garments (sleeve and glove), nighttime bandaging with low stretch Comprilan bandages, and daily Flexitouch treatment over 1 hour every evening. Arm III: Patients undergo daily compression with garments (sleeve and glove) and daily Flexitouch treatment over 1 hour every evening. In all arms, treatment continues for 3 months.

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	60 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Single (Investigator)
Primary Purpose:	Supportive Care
Official Title:	A Pilot, Randomized, Single-Blind Study to Assess the Efficacy of the Flexitouch® Lymphedema System in Reducing Lymphedema in Patients Treated for Breast Cancer
Study Start Date :	July 2009
Actual Primary Completion Date :	January 2011

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Active Comparator: Arm I; Patients undergo complex decongestive therapy comprising daily compression garment (sleeve and glove) use, daily manual lymphatic drainage (self-administerd), and nighttime bandaging with low stretch Comprilan bandages.	Other: questionnaire administration; Ancillary studies Other: lymphedema management
Experimental: Arm II; Patients undergo daily compression with garments (sleeve and glove), nighttime bandaging with low stretch Comprilan bandages, and daily Flexitouch treatment over 1 hour every evening.	Other: questionnaire administration; Ancillary studies Other: lymphedema management
Experimental: Arm III; Patients undergo daily compression with garments (sleeve and glove) and daily Flexitouch treatment over 1 hour every evening.	Other: questionnaire administration; Ancillary studies Other: lymphedema management

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Upper extremity volume measured by circumferential measurements and by CT imaging [ Time Frame: At baseline, monthly for 3 months (circumferential measurements only), and end of study ]
2. Signs and symptoms of acute infection

Secondary Outcome Measures :

1. Weight [ Time Frame: At baseline and then monthly for 3 months ]
2. BMI [ Time Frame: At baseline and then monthly for 3 months ]
3. Upper body function, based on the Disability of Arm, Shoulder, and Hand Scale (DASH) [ Time Frame: At baseline and then monthly for 3 months ]
4. Functional assessment, based on the Functional Assessment of Cancer Therapy Breast + 4 (FACT+4) [ Time Frame: At baseline and then monthly for 3 months ]
5. Quality of life, based on the Functional Assessment of Cancer Therapy Breast (FACT-B) [ Time Frame: At baseline and then monthly for 3 months ]

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	Child, Adult, Senior
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion

• Subjects must have a known, clinical diagnosis of stage II lymphedema as verified by a physician specializing in this disorder
• Subjects must have had a unilateral mastectomy, lymph node (LN) dissection and/or radiation therapy for the treatment of primary breast cancer
• Subjects must have completed their course of adjuvant chemotherapy
• Clinical assessment of lymphedema demonstrating at least 10% difference between the volumes of the affected and opposite limbs at the time of enrollment
• Subjects must be completing phase I of their CDT for their initial onset of lymphedema or for an acute flare of lymphedema
• Subjects must be capable of giving informed consent Exclusion
• History of prior trauma and/or surgery in the affected limb other than that for treatment of breast cancer
• Patients with recurrent breast cancer
• History of bilateral breast cancer
• Subjects currently receiving other therapies for lymphedema
• Subjects with renal, liver, and/or heart dysfunction
• Open wounds or web syndrome
• Active/acute infection (cellulitis)
• Acute DVT/Thrombophlebitis
• Decompensated or untreated congestive heart failure
• Pulmonary embolism - Pregnancy as confirmed by urine test; all patients of child bearing potential will be required to have a urine pregnancy test
• Subjects cannot be homeless persons
• Concomitant chemotherapy and radiation treatment during this study is not permitted

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

United States, Pennsylvania
Abramson Cancer Center of The University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104

Sponsors and Collaborators

Abramson Cancer Center of the University of Pennsylvania

Investigators

Principal Investigator:	Abass Alavi	Abramson Cancer Center of the University of Pennsylvania

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Alavi, Abass, Abramson Cancer Center of The University of Pennsylvania
ClinicalTrials.gov Identifier:	NCT01019512 History of Changes
Other Study ID Numbers:	UPCC 02109; NCI-2009-01415
First Posted:	November 24, 2009
Last Update Posted:	March 25, 2015
Last Verified:	March 2015

Additional relevant MeSH terms:

Breast Neoplasms; Lymphedema; Neoplasms by Site; Neoplasms	Breast Diseases; Skin Diseases; Lymphatic Diseases